-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 5, Osaikang issued an announcement stating that its wholly-owned subsidiary, Jiangsu Osaikang, had recently received the "Notice of Acceptance" for the ASKC202 new drug clinical trial application issued by the National Medical Products Administration
ASKC202 tablet is a Class 1 new drug with independent intellectual property rights, and is a potent and highly selective oral small molecule c-MET inhibitor
As a small molecule inhibitor targeting c-MET, ASKC202 has demonstrated its activity in a series of preclinical tumor models, and is expected to provide new treatment options for patients with abnormal tumors in the c-MET pathway